Skip to content Skip to footer
Subscribe Now
Insights+: EMA Marketing Authorization of New Drugs in August 2024
INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in August 2024

Shots:   The EC has approved to 5 Biologics and 3 New Chemical Entities in August 2024, leading to treatments for patients and advances in the healthcare industry  The major highlighted drugs were Johnson & Johnson’s Balversa to treat Metastatic Urothelial Carcinoma (mUC) and Takeda’s Adzynma for Congenital Thrombotic Thrombocytopenic Purpura (cTTP) PharmaShots has compiled a list…
September 24, 2024

Read more

Viewpoints_Manojkumar Bupathy
VIEWPOINTS

Advancing Cancer Therapy Delivery: Manojkumar Bupathy from Rocky Mountain Cancer Centers in Conversation with PharmaShots

Shots: Addressing a high unmet medical need, PharmaShots had a riveting dialogue exchange with Manojkumar Bupathy from Rocky Mountain Cancer Centers Manojkumar shared insights from the real-world study that analysed the treatment pattern and clinical outcomes in patients with locally advanced/metastatic urothelial carcinoma  The study reveals that four out of the ten patients received only…
August 20, 2024

Read more